TRAIL attenuates the development of atherosclerosis in apolipoprotein E deficient mice

Atherosclerosis

Volumn 215, Issue 2, 2011, Pages 348-354

  Watt, Victoria ^a   Chamberlain, Janet ^a   Steiner, Tanja ^a   Francis, Sheila ^a   Crossman, David ^a,b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Apolipoprotein E deficient mice; Apoptosis; Atherosclerosis; TRAIL

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN E; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; AORTA SINUS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIETARY INTAKE; ENDOTHELIUM; GENE DELETION; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; DISEASE MODELS, ANIMAL; MICE; MYOCYTES, SMOOTH MUSCLE; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 79953060191     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.01.010     Document Type: Article

References (21)

1. Pan G.O.R.K., Chinnaiyan A.M., Gentz R., et al. The receptor for the cytotoxic ligand TRAIL. Science 1997, 276:111-113.
2. Degli-Eposti M.A., Smolak P.J., Walczak H., et al. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med 1997, 186:1165-1170.
3. Emery J.G., McDonnell P., Burke M.B., et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998, 273(23):14363-14367.
4. Daniels R.A., Turley H., Kimberley F.C., et al. Expression of TRAIL and TRAIL receptors in normal and malignant tissues. Cell Res 2005, 15:430-438.
5. Choi J.W., Song J.S., Pai S.H. Associations of serum TRAIL concentrations, anthropometric variables, and serum lipid parameters in healthy adults. Ann Clin Lab Sci 2004, 34(4):400-404.
6. Lub-de Hooge M.N., de Vries E.G., de Jong S., et al. Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus. Ann Rheum Dis 2005, 64(6):854-858.
7. Kimberley F.C., Screaton G.R. Following a TRAIL: update on a ligand and its five receptors. Cell Res 2004, 14(5):359-372.
8. Secchiero P., Zerbinati C., Rimondi E., et al. TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells. Cell Mol Life Sci 2004, 61:1965-1974.
9. Alladina S.J., Song J.H., Davidge S.T., Hao C., Easton A.S. TRAIL-induced apoptosis in human vascular endothelium is regulated by phosphatidylinositol 3-kinase/Akt through the short form of cellular FLIP and Bcl-2. J Vasc Res 2005, 42:337-347.
10. Li J.H., Kirkiles-Smith N.C., McNiff J.M., et al. TRAIL induces apoptosis and inflammatory gene expression in human endothelial cells. J Immunol 2003, 171(3):1526-1533.
11. Sato K., Niessner A., Kopecky S.L., et al. TRAIL-expressing T cells induce apoptosis of vascular smooth muscle cells in the atherosclerotic plaque. J Exp Med 2006, 203(1):239-250. 10.1084/jem. 20051062.
12. Secchiero P., Gonelli A., Carnevale E., et al. TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation 2003, 107(17):2250-2256.
13. Kavurma M.M., Bennett M.R. Expression, regulation and function of trail in atherosclerosis. Biochem Pharmacol 2008, 75(7):1441-1450.
14. Michowitz Y., Goldstein E., Roth A., et al. The involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosis. J Am Coll Cardiol 2005, 45(7):1018-1024.
15. Schoppet M., Al-Fakhri N., Franke F.E., et al. Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-{kappa}B ligand in Monckeberg's sclerosis and atherosclerosis. J Clin Endocrinol Metab 2004, 89(8):4104-4112.
16. Chan J., Prado-Lourenco L., Khachigian L.M., et al. TRAIL promotes VSMC proliferation and neointima formation in a FGF-2-Sp1 phosphorylation-, and NFkappaB-dependent manner. Circ Res 2010, 106(6):1061-1071.
17. Secchiero P., Candido R., Corallini F., et al. Systemic tumor necrosis factor-related apoptosis-inducing ligand delivery shows antiatherosclerotic activity in apolipoprotein e-null diabetic mice. Circulation 2006, 114(14):1522-1530.
18. Rus V., Zernetkina V., Puliaev R., et al. Increased expression and release of functional tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by T cells from lupus patients with active disease. Clin Immunol 2005, 117(1):48-56.
19. + T cell killing of antigen-presenting macrophages. J Immunol 2000, 164:2897-2904.
20. Schreyer S.A., Vick C.M., LeBoeuf R.C. Loss of lymphotoxin-alpha but not tumor necrosis factor-alpha reduces atherosclerosis in mice. J Biol Chem 2002, 277(14):12364-12368. 10.1074/jbc. M111727200.
21. Kanters E., Pasparakis M., Gijbels M.J., et al. Inhibition of NF-{kappa}B activation in macrophages increases atherosclerosis in LDL receptor-deficient mice. J Clin Invest 2003, 112(8):1176-1185. 10.1172/JCI200318580.